Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC Presented ByDr Justin F. Gainor, Massachusetts General Hospital, USA TrialPhase 1, ARROW ConferenceASCO 2019 TypePeer-reviewed article 15 July 2019 19:23